CR20120147A - Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo - Google Patents

Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo

Info

Publication number
CR20120147A
CR20120147A CR20120147A CR20120147A CR20120147A CR 20120147 A CR20120147 A CR 20120147A CR 20120147 A CR20120147 A CR 20120147A CR 20120147 A CR20120147 A CR 20120147A CR 20120147 A CR20120147 A CR 20120147A
Authority
CR
Costa Rica
Prior art keywords
maitansinoids
antibody
new
prepare conjugates
conjugates
Prior art date
Application number
CR20120147A
Other languages
English (en)
Inventor
Herve Bouchard
Alain Commerconi
Claudia Fromond
Vicent Mikol
Fabienne Parker
Ingrid Sasson
Daniel Tavares
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20120147A publication Critical patent/CR20120147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I) donde ALK es un grupo alquileno (C1,-c6); X1 y X2 son cada uno independientemente uno de los grupos siguientes: -CH=CH
CR20120147A 2009-10-02 2012-03-26 Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo CR20120147A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305939 2009-10-02

Publications (1)

Publication Number Publication Date
CR20120147A true CR20120147A (es) 2012-06-01

Family

ID=41698152

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120147A CR20120147A (es) 2009-10-02 2012-03-26 Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo

Country Status (24)

Country Link
US (1) US20120276124A1 (es)
EP (1) EP2483279A1 (es)
JP (1) JP2013506653A (es)
KR (1) KR20120091166A (es)
CN (1) CN102741260A (es)
AR (1) AR078471A1 (es)
AU (1) AU2010302247A1 (es)
BR (1) BR112012007305A2 (es)
CA (1) CA2774916A1 (es)
CL (1) CL2012000820A1 (es)
CR (1) CR20120147A (es)
EA (1) EA201270473A1 (es)
EC (1) ECSP12011756A (es)
IL (1) IL218740A0 (es)
MA (1) MA33702B1 (es)
MX (1) MX2012003998A (es)
NI (1) NI201200051A (es)
NZ (1) NZ599045A (es)
PE (1) PE20121534A1 (es)
TN (1) TN2012000115A1 (es)
TW (1) TW201117814A (es)
UY (1) UY32913A (es)
WO (1) WO2011039721A1 (es)
ZA (1) ZA201202328B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
TW201116297A (en) * 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
SI2691155T1 (sl) 2011-03-29 2019-03-29 Immunogen, Inc. Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
IN2015DN02349A (es) * 2012-10-24 2015-08-28 Polytherics Ltd
NO2789793T3 (es) * 2012-10-24 2018-01-27
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
US20160143914A1 (en) * 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
JP6608823B2 (ja) 2013-08-26 2019-11-20 レゲネロン ファーマシューティカルス，インコーポレーテッド マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用
CN103483357B (zh) * 2013-10-12 2015-11-18 齐鲁制药有限公司 一种抗体-美登素偶联物的中间体新晶型及其制备方法
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
US9562059B2 (en) * 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
JP6802840B2 (ja) 2015-06-09 2020-12-23 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド 抗体薬物複合体、中間体、その製造方法、薬学的組成物及び応用
JP6638970B2 (ja) * 2015-06-30 2020-02-05 株式会社 東北テクノアーチ ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法
EP3408271B1 (en) 2016-01-25 2023-01-11 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CN1795009B (zh) 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
CA2525367A1 (en) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Use of citrate lyase inhibitors and tricarboxylate transporter inhibitors in the treatment of cancer
PT3524611T (pt) 2003-05-20 2021-04-01 Immunogen Inc Agentes citotóxicos melhorados compreendendo novos maitansinóides
US20050123549A1 (en) 2003-07-21 2005-06-09 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2617953C (en) 2005-08-09 2013-12-17 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
AU2006283726C1 (en) * 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR20100137585A (ko) * 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
TW201116297A (en) * 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor

Also Published As

Publication number Publication date
AR078471A1 (es) 2011-11-09
CN102741260A (zh) 2012-10-17
US20120276124A1 (en) 2012-11-01
ZA201202328B (en) 2014-06-25
TW201117814A (en) 2011-06-01
NI201200051A (es) 2012-08-09
KR20120091166A (ko) 2012-08-17
JP2013506653A (ja) 2013-02-28
BR112012007305A2 (pt) 2016-12-06
EA201270473A1 (ru) 2013-02-28
MX2012003998A (es) 2012-04-20
AU2010302247A1 (en) 2012-04-26
UY32913A (es) 2011-04-29
EP2483279A1 (en) 2012-08-08
IL218740A0 (en) 2012-06-28
NZ599045A (en) 2013-09-27
WO2011039721A1 (en) 2011-04-07
PE20121534A1 (es) 2012-12-03
TN2012000115A1 (en) 2013-09-19
ECSP12011756A (es) 2012-07-31
MA33702B1 (fr) 2012-10-01
CL2012000820A1 (es) 2012-08-31
CA2774916A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CR20120147A (es) Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo
CY1120682T1 (el) Ενωσεις για την προστασια κυτταρων
CR20120334A (es) Derivados de imidazopiridina como inhibidores de jak
CR20120348A (es) Nuevos compuestos tricíclicos
ES2570569T3 (es) Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
CR20110135A (es) INHIBIDORES DE cMET
NI201200174A (es) Derivados de carbamato de hexafluoroisopropilo, su preparación y su aplicación en terapéutica.
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
BR112013004341A2 (pt) composições pesticidas
CR11861A (es) Compuestos organicos
ECSP11011430A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
CO6700838A2 (es) Compuestos sustituidos de banzamida
PE20151779A1 (es) Xantinas sustituidas y metodos de uso de las mismas
CR11370A (es) Inhibidores de quinasas simil polo
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
UY32077A (es) Inhibidores de quinasa tipo polo
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
CY1119492T1 (el) Παραγωγα καρβαμικα/ουριας
AR098270A1 (es) Poliéster terminado en epoxi
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CO7350647A2 (es) Polisacárido alternano que es funcionalizado con grupos de nitrógeno que pueden ser protonados, o con grupos de nitrógeno permanentemente cargados positivamente
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CO6751286A2 (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
UY33812A (es) Generador Eólico Sincrónico